As health care facilities across the country are finding ways to cut costs without sacrificing quality care, the Memorial Sloan-Kettering Cancer Center decided not to offer the drug ziv-aflibercept (Zaltrap) for the treatment of colorectal cancer.
At the eighth annual Chicago Supportive Oncology Conference, Dr. Thomas Smith said the center's decision could be a game-changer. Meanwhile, Dr. Anthony Back stressed the importance of talking to patients about cost of treatment.